Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran

Mehrdad Payandeh¹, Masoud Sadeghi²,³, Edris Sadeghi²,³

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
²Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Corresponding Author: Masoud Sadeghi, Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Tel: +989185960644
Fax: +9883-3427 6471
Email: Sadeghi_mbrc@yahoo.com

ABSTRACT

Background: Hairy cell leukemia (HCL) is a chronic B-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect. The study aims to evaluate a group of patients with hairy cell leukemia, hospitalized in the Clinic of Hematology and Oncology, Kermanshah, Iran, on a period of 15 years and affect of between cladribine therapy and IFN therapy on the patients with HCL.

Methods: This is a retrospective analysis of 11 patients in the Clinic of Hematology and Oncology, Kermanshah, Iran, between 2004 and 2013. Clinical features at diagnosis, differential count (platelet, Hb and WBC) types of therapy, survival rate and BRAF mutation have been monitored. As a result, cladribine therapy is the best treatment option for patients.

Results: The mean age of patients was 50 years with 100% of men. Approximately 45% of them had splenomegaly at diagnosis. 100% of patients had pancytopenia at diagnosis. 9% of patients had mutation of BRAF V600E. Before of treatment, there were fatigue, weight loss, vomiting, fever, night sweat and itching in all of the patients.

Conclusion: There is presence of hairy cells in peripheral blood and bone marrow and was associated with pancytopenia, splenomegaly, myelofibrosis in HCL patients. Also, cladribine therapy is best option for treatment of patients and it is better than IFN.

Keywords: Hairy Cell Leukemia, Splenomegaly, Cladribine

INTRODUCTION

Hairy cell leukemia (HCL) is a chronic B-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect.¹ HCL is more frequent in men than in women (4:1 ratio), appearing around 50 years old.¹ There are approximately 1,000 and 1,600 new cases of HCL per year in the US and Europe, respectively. The prevalence of the disease is unknown, although HCL accounts for 2% of all leukemias, the incidence of HCL increases annually.²

The presence of the BRAF V600E mutation has recently been described in hairy cell leukemia (HCL) but not in other common lymphomas³ (BRAF V600E mutation has been reported in 50% of melanomas, and is present in more than 85% of HCL cases).⁴ Cladribine is a well-known purine nucleoside analog with activities against lymphoproliferative disorders such as HCL,⁵ and immunomodulatory activities of interferon (IFN) can improve or even normalize peripheral blood counts in patients with HCL.⁶ Currently, flow cytometric analysis (FC) and frozen section immunohistochemistry (IHC) represent the only available methods for diagnosis of hairy cell
leukemia (HCL).

Despite the fact that more effective chemotherapeutics are available in the treatment of HCL today, splenectomy still remains a valid treatment option in certain cases. HCL with massive splenomegaly (e.g. >10 cm below costal margin) but low bone marrow involvement can be an indication for splenectomy as first-line treatment.

Flow cytometric analysis shows the expression of CD103+, CD11c+, CD19+, CD20+, CD22+ and CD5 in HCL, while CD10- and CD23- are expressed in some cases.

The clinical presentations included splenomegaly, hepatomegaly, fatigue, pallor, weight loss, infections, rarely lymphadenopathy. In 10% of cases, the disease is asymptomatic but in the rest of cases abdominal pain and the laboratory features such as anemia, monocytopenia and neutropenia were commonly more.

The study aims to evaluate the efficacy of treatment with cladribine and IFN in a group of 11 patients with hairy cell leukemia hospitalized at the Clinic of Hematology and Oncology, Kermanshah, Iran, over a period of 15 years.

SUBJECTS AND METHODS

This is a retrospective analysis of 11 patients at the Clinic of Hematology and Oncology, Kermanshah, Iran, between 2004 and 2013. Clinical features including splenomegaly (n=6), fatigue, weight loss, vomiting, fever, pallor, lymphadenopathy were identified in all patients at initial diagnosis. We determined differential count, types of therapy, survival rate and BRAF mutation in all patients. Complete response (CR) to multiple different drug types (consisted of cladribine and/or interferon) was defined as the disappearance of all clinical features, normal spleen size, WBC, hemoglobin and platelet. Partial response (PR) to drugs required the existence of at least clinical features and abnormality in WBC, hemoglobin and platelet.

Statistical Analysis

Survival was determined from date of first administration of cladribine and/or interferon to death. Kaplan-Meier survival curves (Figure 2) were made with Prism 5 (GraphPad Software). Data (WBC, hemoglobin and platelet) were analyzed using IBM SPSS statistics 19.

RESULTS

Participants were recruited from males with the mean age of 50 years old. Approximately, 45% of who had splenomegaly at the time of diagnosis (Figure 2), while all patients had pancytopenia at diagnosis. 9% of patients had BRAF V600E mutation (Figure 2). Before treatment, median WBC, hemoglobin and platelets were 2681/µL, 7.25 g.dL and 56100 /µL, respectively (Figure 1).

Before treatment, fatigue, weight loss, vomiting, fever, night sweat and itching were reported in all patients. Figure 2 shows the effect of drug treatment in patients after 115 months. Three patients (No.2, 7, 8) received interferon alpha, 2 of whom had a PR and 1 had a CR. seven patients (No.1, 3, 5, 6, 9, 10, 11) received cladribine, 6 of whom had a CR and 1 achieved PR. one patient (No.4) who had received cladribine and interferon showed CR.

Of the 11 patients, one (No.7) died after 115 months of treatment with interferon. The mean survival time after first administration of cladribine and/or interferon was 56.9 months. The survival rate among patients was 90%.

DISCUSSION

Diagnosis of HCL was based on the presence of hairy cells in peripheral blood and bone marrow and was associated with pancytopenia, splenomegaly, myelofibrosis. Bone marrow, spleen and liver are characteristically infiltrated by leukemic B cells showing abundant cytoplasm with “hairy” projections and unique immunophenotypic features.

In this study, all patients were associated with pancytopenia and splenomegaly, and bone marrow and spleen were infiltrated hairy cells. In this study, all patients were associated with pancytopenia and splenomegaly, and bone marrow and spleen were infiltrated hairy cells. While little is known about the biological role of 4/5 affected genes, BRAF represents the most frequently mutated gene encoding a protein kinase in human cancers.
Interestingly, the same amino acid change (V600E) identified in our patient represents a mutational hotspot in melanomas and papillary thyroid cancers, where its oncogenic activity has been extensively documented. Moreover, dysregulation of the mitogen-activated protein kinase (MAPK) pathways, of which BRAF is a component, was previously implicated in HCL pathogenesis. In conclusion, BRAF V600E mutation seems to have an important role in the pathogenesis of HCL if it is not even the disease-defining genetic event. 9% of patients had BRAF mutation (n=1). The presence of BRAF mutation in most individuals with HCL and the response of these patients have suggested that BRAF mutations are an oncogenic driver in this disease, but in this study BRAF V600E mutation appeared not to have very important role in HCL pathogenesis. Hence, in order to achieve a reasonable outcome, it is recommended to recruit more participants from other parts of Iran.

In a study on 28 cases of HCL, the median age of patients was 47 years with male predominance (M:F=6:1), and in another study on 39 HCL patients, the median age of patients was 52 years with a high frequency in men. This study included only male participants with a median age 50 years. According to these studies, according to 4 earlier studies, men have greater risk of HCL and patients with HCL are usually middle-aged men.

Cladribine has been identified as a lymphocyte-specific agent and it induces protracted remissions in patients with hairy cell leukemia. The results indicate that HCL is potentially curable after cladribine treatment. HCL can be well-controlled with Cladribine: overall complete response rates ranged from 76 to 98%, median disease-free survival of 16 years, normal lifespan and rare HCL-related deaths. The response of hairy cell leukemia (HCL) to IFN-α is one of the most dramatic and specific effects in the whole of clinical oncology, but the mechanism of action of IFN-α in HCL remains unclear. Although IFN-α is highly active in HCL, IFN-α is not curative in this disease. Poor response to alpha-IFN-α treatment could likely be related to a peculiar immunological phenotype of the hairy cell.
In this study, 6 of 7 patients treated with cladribine had CR, but among patients (n=3) treated with IFN–α, 1 achieved CR and 1 died after 115 months. The results of a study by Damasio et al on 169 patients showed that the majority of patients (n=169) treated with IFN had PR. Therefore, IFN therapy cannot be deemed effective in all HCL patients, but cladribine is effective for treatment of patients, and induces high CR rates like the study conducted by Davies et al.15

CONCLUSION
Diagnosis of HCL is sometimes difficult, but WBC<3000, hemoglobin<10, platelet<100000 and also fatigue, weight loss, vomiting, fever, night sweat and itching in patient are signs of HCL. The presence of hairy cells in peripheral blood and bone marrow was associated with pancytopenia, splenomegaly and myelofibrosis in HCL patients. Moreover, our results have shown that cladribine therapy is the best option for treatment of HCL.

REFERENCES
1. Găman AM. Hairy cell leukemia--a rare type of leukemia. A retrospective study on 39 patients. Rom J Morphol Embryol. 2013;54(3):575-9.
2. Shackelford RE, Heldmann M, Eskandari F, et al. Marked retroperitoneal lymphadenopathy in hairy cell leukemia: A case report. Case Rep Oncol. 2013 Sep 28;6(3):493-6.
3. Laurini JA, Aoun P, Iqbal J, et al. Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012 Dec;138(6):877-83.
4. Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012:660-6.
5. Cai B, Wang S, Huang J, et al. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res. 2013; 5(1):36-46.
6. Mæveis V, Mey U, Schmidt-Wolf G, et al. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J. 2014 Feb 14; 4:e184.
7. Morgan EA, Yu H, Pinkus JL, et al. Immunohistochemical detection of hairy cell leukemia in paraffin sections using a highly effective CD103 rabbit monoclonal antibody. Am J Clin Pathol. 2013 Feb;139(2):220-30.
8. Monterrosa J, Chandana S. Images in clinical medicine. Massive splenomegaly in hairy-cell leukemia. N Engl J Med. 2012 Nov 29;367(22):2133.
9. Pande P, Yelikar BR, Kumar U M. A hairy cell leukaemia variant - a rare case report. J Clin Diagn Res. 2013 Feb; 7(2):358-60.
10. Galani KS, Subramanian PG, Gadage VS, et al. Clinicopathological profile of Hairy cell leukaemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol. 2012 Jan-Mar; 55(1):61-5.
11. Pande P, Yelikar BR, Kumar U M. A hairy cell leukaemia variant - a rare case report. J Clin Diagn Res. 2013 Feb;7(2):358-60.
12. Chatterjee T, Panigrahi I, Mahapatra M, et al. Hairy cell leukaemia: clinical, pathological and ultrastructural findings in Asian-Indians. Indian J Cancer. 2008 Apr-Jun; 45(2):41-4.
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–54.
14. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol; 2010;80:561–7.
15. Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review) Oncol Rep 2012;60:22:671.
16. Kamiguti AS, Harris RJ, Slupsky JR, et al. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene. 2003; 22:2272–84.
17. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 Jun 16; 364(24):2305-15.
18. Sigal DS, Miller HJ, Schram ED, et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood; 2010 Oct 21. 116(16):2884-96.
19. Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010 Mar 11; 115(10):1893-6.
20. Baker PK, Pettitt AR, Slupsky JR, et al. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood. 2002 Jul 15;100(2):647-53.
21. Steis RG, Smith JW, Urba WJ, et al. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood. 1991 Feb 15;77(4):792-8.
22. Lauria F, Zinzani PL, Raspadori D, et al. Relationship between immunological phenotype and hematological response to alpha-IFN treatment in 35 patients with hairy cell leukemia. Eur J Haematol Suppl. 1990;52:3-6.
23. Damasio EE, Frassoldati A. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma. 1994;14 Suppl 1:95-8.